5-羟基-1-甲基-1,2-二氢吡啶-2-酮 | 29094-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-羟基-1-甲基-1,2-二氢吡啶-2-酮
• 英文名称: 5-hydroxy-1-methyl-2-pyridone
• 英文别名: 5-hydroxy-1-methylpyridin-2(1H)-one；1-Methyl-3-hydroxypyridon-(6)；5-hydroxy-1-methyl-1H-pyridin-2-one；5-hydroxy-1-methylpyridin-2-one
• CAS: 29094-75-5
• 化学式: C₆H₇NO₂
• 分子量: 125.127
• InChiKey: JTZUTFHXEWRKJR-UHFFFAOYSA-N

物化性质

• 沸点：
  266.6±40.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-羟基-1-甲基-1,2-二氢吡啶-2-酮 、 2,6-dibenzyloxy-3-iodopyridine 在 2,2'-联吡啶 、 copper(l) iodide 、 caesium carbonate 、 palladium on activated charcoal 、 氢气 作用下， 以 N,N-二甲基甲酰胺 、 乙醇 为溶剂， 生成 C₁₁H₁₂N₂O₄
  参考文献：
  名称：

  [EN] N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
  [FR] DÉGRONS ET DÉGRONIMÈRES À LIAISON N/O POUR LA DÉGRADATION DE PROTÉINES

  摘要：

  这项发明提供了具有E3泛素连接酶靶向基团（Degrons）的Degronimers，这些Degrons可以与已选择进行体内降解的蛋白质的靶向配体相连接，以及它们的使用方法和组合物，以及它们的制备方法。该发明还提供了可用于治疗由cereblon或Ikaros家族蛋白介导的疾病的Degrons，以及其使用方法和组合物，以及其制备方法。

  公开号：

  WO2018237026A1
• 作为产物：
  描述：

  1-甲基-2-吡啶酮 在 葡萄糖 、 Escherichia coli JM₁₀₉(DE₃)pDTG₁₄₁ 作用下， 以 phosphate buffer 为溶剂， 反应 22.0h， 生成 5-羟基-1-甲基-1,2-二氢吡啶-2-酮
  参考文献：
  名称：

  Dioxygenase-catalysed formation of dihydrodiol metabolites of N-methyl-2-pyridone

  摘要：

  IPTG-induced cells of a recombinant strain of Escherichia coli JM109(DE3)pDTG141 expressing naphthalene dioxygenase from Pseudomonas sp. NCIB 9816-4 oxidized specifically N-methyl-2-pyridone to give the corresponding cis5,6-dihydro-5,6-dihydroxy derivative as a major product. A small amount of the cis-3,4-dihydro-3,4-dihydroxy isomer was simultaneously formed. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)00541-4

文献信息

• [EN] PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA CONTENANT DE LA PYRROLIDINE ET DE LA BICYCLOHÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021094312A1

  公开（公告）日：2021-05-20

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病，由帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍），具有Lewy小体的痴呆，多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• Novel pyridones and their use as modulators of serine hydrolase enzymes
  申请人：Dalhousie University

  公开号：US20020049330A1

  公开（公告）日：2002-04-25

  This invention relates to a compound of formula I: 1 or a pharmaceutically acceptable salt thereof; in which preferably R 3 , R 4 and R 6 are each hydrogen; X is C═O or CH 2 ; and R 7 and R 8 are each independently selected from the group consisting of hydrogen, (C 1 -C 12 )alkyl, (C 3 -C 8 )cycloalkyl and (C 1 -C 2 )alkyl(C 6 -C 14 )aryl; or R 7 and R 8 when taken together form a (C 2 -C 7 )alkylene group; or —NR 7 R 8 together forms a (C 2 -C 14 )heterocyclic or substituted (C 2 -C 14 )heterocyclic. Such compounds modulate the activity of serine hydrolases and can be used in pharmaceutical compositions for the treatment of Alzheimer's disease.

  这项发明涉及一种化合物，其化学式为I:1或其药用盐；其中，最好的情况是R3、R4和R6分别为氢；X为C═O或CH2；而R7和R8分别独立地选自氢、(C1-C12)烷基、(C3-C8)环烷基和(C1-C2)(C6-C14)芳基的组合；或者当R7和R8一起形成(C2-C7)烷基基团时；或者—NR7R8一起形成(C2-C14)杂环或取代的(C2-C14)杂环。这些化合物调节丝氨酰水解酶的活性，可用于治疗阿尔茨海默病的药物组合物中。
• WO2020154571A5
  申请人：——

  公开号：WO2020154571A5

  公开（公告）日：2023-02-02
• COMPOUNDS AND USES THEREOF
  申请人：Yumanity Therapeutics, Inc.

  公开号：EP3914593A1

  公开（公告）日：2021-12-01
• N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
  申请人：C4 Therapeutics, Inc.

  公开号：US20200140456A1

  公开（公告）日：2020-05-07

  This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.